1H3.SI Stock Doubles on May 4 as Clearbridge Health Surges 100%

Clearbridge Health Limited’s 1H3.SI stock has captured attention on the Singapore Exchange with a dramatic 100% surge to S$0.002 during intraday trading on May 4, 2026. The healthcare provider, which operates imaging services, medical clinics, and pharmaceutical distribution across Singapore and Southeast Asia, saw trading volume plummet to just 300 shares compared to its average of 3.67 million. This extreme price movement reflects the stock’s micro-cap status and illiquidity. With a market cap of just S$4.3 million and shares outstanding exceeding 4.2 billion, 1H3.SI stock remains highly speculative. Meyka AI’s analysis platform tracks this volatile healthcare play as it navigates challenging fundamentals and technical headwinds.

1H3.SI Stock Price Action and Market Sentiment

1H3.SI stock opened at S$0.001 and climbed to a day high of S$0.002, marking a perfect 100% intraday gain. However, the move came on exceptionally light volume of just 300 shares, representing only 0.008% of average daily volume. This suggests the price spike may lack conviction and liquidity support.

Trading Activity: The stock trades near its 52-week low of S$0.001 and remains far below its 52-week high of S$0.005. Year-to-date performance shows a 50% decline, while the three-year and five-year charts reveal a devastating 75% loss. The 50-day moving average sits at S$0.00164, while the 200-day average stands at S$0.00229, both well above current levels.

Liquidation Concerns: Negative technical indicators compound the bearish picture. The Money Flow Index (MFI) reads 1.26, signaling severe oversold conditions. The Relative Strength Index (RSI) at 44.91 suggests neutral momentum, while Williams %R at -100 indicates extreme weakness. Rate of Change (ROC) shows -50%, reflecting sustained selling pressure.

Financial Metrics and Valuation Analysis

Clearbridge Health’s fundamentals paint a troubling picture for 1H3.SI stock investors. The company reported negative earnings per share (EPS) of -S$0.0039 trailing twelve months, resulting in a meaningless negative PE ratio. Revenue per share reached only S$0.00302, while net income per share deteriorated to -S$0.0039.

Profitability Breakdown: Operating margins turned deeply negative at -13.17%, while net profit margins collapsed to -129.43%. Return on equity (ROE) stands at a disastrous -164.2%, and return on assets (ROA) measures -130.6%. Free cash flow per share came in negative at -S$0.000825, indicating the company burns cash operationally. Track 1H3.SI on Meyka for real-time updates on these deteriorating metrics.

Valuation Ratios: The price-to-book ratio of 0.95 suggests modest discount to book value, yet the price-to-sales ratio of 0.43 appears cheap. However, these metrics offer little comfort given negative earnings and cash burn. Debt-to-equity stands at 0.42, indicating moderate leverage in a struggling business.

Meyka AI Grade and Forecast Outlook

Meyka AI rates 1H3.SI stock with a grade of C+ based on a score of 58.77 out of 100, with a recommendation to HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating reflects significant structural challenges despite modest valuation metrics.

Price Forecast Model: Meyka AI’s forecast model projects 1H3.SI stock reaching S$0.00512 within one year, implying 156% upside from current levels. Three-year projections target S$0.01168, while five-year forecasts suggest S$0.01822. These projections assume operational turnaround and improved profitability. Forecasts are model-based projections and not guarantees of future performance.

Sector Context: Clearbridge Health operates in Singapore’s Healthcare sector, which averages a PE ratio of 22.32 and ROE of 13.41%. The company’s metrics lag sector averages significantly, highlighting competitive disadvantages. The healthcare industry includes stronger players like IHH Healthcare and Raffles Medical Group with superior financial profiles.

Operational Challenges and Business Segments

Clearbridge Health Limited operates through three segments: Strategic Investments, Healthcare Systems, and Medical Clinics/Centres. The company provides imaging services including X-ray, CT scans, MRI, and ultrasound across Singapore, Philippines, Hong Kong, and Malaysia. It also offers general health screening, vaccination services, renal care, aesthetics, dental, and orthodontics services.

Operational Metrics: The company employs 1,280 full-time staff across its regional footprint. Days sales outstanding of 113.6 days indicates collection challenges, while inventory turnover of 21.07x shows efficient pharmaceutical product management. Operating cycle of 130.95 days reflects working capital strain.

Cash Flow Deterioration: Operating cash flow per share turned negative at -S$0.000807, while free cash flow per share measured -S$0.000825. The company’s current ratio of 1.51 provides modest liquidity cushion, but negative cash generation threatens sustainability. Earnings announcement scheduled for August 19, 2026 will provide critical updates on turnaround progress.

Final Thoughts

1H3.SI stock experienced a dramatic 100% intraday surge to S$0.002 on May 4, 2026, yet the move lacks fundamental support and occurred on minimal volume. Clearbridge Health Limited faces severe operational headwinds including negative earnings, cash burn, and deteriorating profitability across all metrics. The company’s C+ grade from Meyka AI reflects these challenges, though long-term forecasts project recovery to S$0.00512 within one year. Investors should recognize this as a highly speculative micro-cap healthcare play with significant turnaround risk. The stock’s 75% three-year decline and negative cash flow generation warrant extreme caution. Only risk-toleran…

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.